This Innovator Pharma Stock Rises 127% in 1 Year: New Owner, New Brand, New Name

This innovator pharma stock turned Rs 1 lakh into roughly Rs 2.27 lakh in a single year. It traded near Rs 2,053 on 16 September 2026 against about Rs 906 a year earlier, a verified return of around 127%, placing this innovator pharma stock among the strongest performers on a screen of NSE small-cap stocks ranked by 1-year return, dated 16 September 2026.

The company is Novartis India Ltd (NSE: NOVARTIND), a Mumbai based prescription drug marketer owned by Swiss parent Novartis AG until July 2026 and now controlled by a ChrysCapital led consortium. The Novartis India share price has been driven by a change of ownership and a large brand purchase rather than by earnings. Its brands include Voveran, transplant drugs Neoral, Simulect and Certican, and neurology names Tegrital and Exelon.

Click Here – Get Free Investment Predictions

How Has This Innovator Pharma Stock Performed Across Time Frames?

Almost the entire gain in this innovator pharma stock is recent. The one-year return of approximately 127% is real, but most of it arrived in nine sessions to 10 September 2026, when the share rose roughly 74% and touched a record Rs 2,588.80. The Novartis India share price has since fallen around 21% from that peak.

The table shows verified price returns to 16 September 2026. Periods that could not be checked against continuous price history are omitted.

Period	Price return	Reference close
1 week	Around minus 6%	Rs 2,186 on 9 September 2026
1 month	Around plus 29%	Rs 1,589 on 17 August 2026
3 months	Around plus 55%	Rs 1,324 on 16 June 2026
1 year	Around plus 127%	Rs 906 on 15 September 2025

One more reference point helps. On 19 February 2026, the day before the ownership deal was announced, this innovator pharma stock traded near Rs 830. Everything above that came after the promoter change became public, which shows how event driven this move has been.

Why Did This Innovator Pharma Stock Rise 127% in One Year?

Four events explain the move, three in the last seven months. None is an accounting one-off, but all are corporate actions rather than organic growth, so the re-rating in this innovator pharma stock rests on execution that has not happened yet.

A New Promoter Replaced The Swiss Parent

On 19 February 2026 Novartis AG agreed to sell its entire 70.68% holding to a consortium of WaveRise Investments, ChrysCapital Fund X and Two Infinity Partners for about Rs 1,446 crore. The Novartis India share price jumped roughly 20% the next day to Rs 996.50, pricing in a private equity owner with an appetite for brands.

The deal closed on 29 July 2026. The board was replaced, Dr Vikas Gupta became managing director and chief executive, and the company began dropping all references to the Novartis name within 120 days, subject to approval at its 78th annual general meeting. Buyers of this innovator pharma stock are buying a business that will soon trade under another name.

The Open Offer Was A Non Event

The change of control triggered an open offer for 26% of the equity at Rs 860.64 per share. Only 40 shares were tendered out of 64.19 million, because by then the market price was far above the offer. Public shareholding stayed near 29% and no delisting has been proposed, so nobody should hold this innovator pharma stock expecting a premium exit.

The Minipress Purchase Re-Rated This Innovator Pharma Stock

The sharpest leg of the rally followed board approval on 7 September 2026 to buy the Minipress and Minipres trademarks from Pfizer for approximately Rs 1,250 crore. Minipress XL is a prazosin based brand used in hypertension and in urinary symptoms linked to prostate enlargement.

Industry prescription tracking put the brand's trailing annual sales near Rs 228.6 crore as of July 2026, compounding at about 6.3% over four years against roughly 9% for its category. This innovator pharma stock rose about 51% in three sessions, because the deal adds revenue equal to roughly 65% of FY26 sales in one stroke.

Distribution Brought Back In House

Two smaller announcements added to the story. The company signed an exclusive distribution agreement with Novartis Healthcare Private Ltd for the retina brands Accentrix and Pagenax. The board also decided on 7 August 2026 to end the February 2022 distribution agreement with Dr Reddy's Laboratories from 30 September 2026, regaining direct market access.

Together these moves point to a company being rebuilt as an acquisition platform for established prescription brands. That is the thesis holders of this innovator pharma stock are paying for today.

Check the Univest Screener for Live Fundamentals of High-Return Stocks

What The Financials Say About This Innovator Pharma Stock

The operating numbers have not doubled, and that gap matters for anyone valuing this innovator pharma stock. Revenue for the year to March 2026 was about Rs 354 crore against Rs 356 crore a year earlier, and net profit fell to roughly Rs 93 crore from Rs 101 crore.

Quarter	Revenue (Rs cr)	Operating profit (Rs cr)	Operating margin	Net profit (Rs cr)	EPS (Rs)
Q1 FY27 (Jun 2026)	104	35	34%	32	13.05
Q4 FY26 (Mar 2026)	91	21	23%	25	10.23
Q3 FY26 (Dec 2025)	86	22	26%	16	6.52
Q2 FY26 (Sep 2025)	90	24	26%	24	9.81

The June 2026 quarter is the strongest in two years. Revenue near Rs 104 crore came with a 34% operating margin and net profit of about Rs 32 crore, up roughly 17% year on year. One quarter is not a trend, but the cost base was clearly tightened. Those numbers are the base against which this innovator pharma stock must now be judged.

The balance sheet is the real attraction. Debt to equity is 0.00, book value per share about Rs 331, return on capital employed around 16.3% and return on equity roughly 11.4%. A debt free balance sheet is what lets a new owner fund brand purchases, and much of why this innovator pharma stock was bought.

Who Owns This Innovator Pharma Stock Now?

Promoter holding has changed in identity, not in size. The ChrysCapital led consortium holds 70.68%, exactly the stake Novartis AG held before exiting. Public shareholders own about 27.78%.

Institutional participation is thin. Domestic institutions hold around 1.39% and foreign institutions about 0.15% across roughly 36,700 shareholders, unusually low for a listed drugmaker. That cuts both ways for this innovator pharma stock, allowing sharp moves on small volumes.

Valuation Check On This Innovator Pharma Stock

After a 127% run the valuation is no longer undemanding. At about Rs 2,053 this innovator pharma stock trades at a trailing price to earnings ratio near 52 against an industry average close to 51, and at roughly 6.2 times book value. Any buyer of this innovator pharma stock at current levels is paying for the platform, not for the trailing profit.

Metric	Value
Market capitalisation	Around Rs 5,100 crore
Price to earnings (TTM)	Approximately 52
Industry price to earnings	Approximately 51
Price to book	Approximately 6.2
Earnings per share (TTM)	Rs 39.60
Book value per share	Rs 331
Return on equity	11.4%
Return on capital employed	16.3%
Debt to equity	0.00
Dividend yield	Approximately 1.1%
52-week high	Rs 2,588.80
52-week low	Around Rs 750

On payouts, the only dividend in the window was a final Rs 25 per share with an ex-date of 23 July 2025. No special dividend has been declared, and no part of the one-year gain in this innovator pharma stock came from a payout, bonus issue or stock split. The 127% figure is clean price appreciation.

Risks Every Buyer Of This Innovator Pharma Stock Should Weigh

The first risk is the shape of the move. A gain of roughly 74% in nine sessions followed by a fall of around 21% in four is not normal price behaviour, and anyone entering this innovator pharma stock now is buying after the re-rating.

The second is funding. The Minipress purchase is worth about Rs 1,250 crore against a net worth of roughly Rs 817 crore and a market value near Rs 5,100 crore, close to 5.5 times the brand's annual sales. Paying for it likely needs debt, an equity raise or both, which would end the debt free position supporting the multiple on this innovator pharma stock.

The third is transition risk. The company is changing its name, board, chief executive and distribution arrangement at once. Ending the Dr Reddy's agreement on 30 September 2026 means building direct reach, and slippage will show in the December 2026 quarter. A transition of this scale is the single largest swing factor for this innovator pharma stock over the next year.

The fourth is liquidity and volatility, the standard small-cap warning, which applies with force to this innovator pharma stock. Daily volumes have swung from under 4,000 shares in quiet August sessions to more than 2.2 million on 10 September 2026. Price bands have been hit in both directions and the free float is small, so exiting a position of size on a weak day can be hard.

The fifth is coverage. No verified brokerage research could be found and the scrip has no derivatives segment, so investors in this innovator pharma stock work without the usual guardrails. On the positive side, no insolvency proceeding, auditor qualification, promoter pledge or surveillance action has been reported.

Download the Univest iOS App or Univest Android App to track the Novartis India share price live

Novartis India Share: Analyst View

Formal sell side coverage of the Novartis India share is effectively absent. The company is small, the free float limited and the structure has just changed hands, so most research desks have not published on it. The Novartis India share price is being set by flow and news, not by estimates.

What can be said factually is that the June 2026 quarter showed margin recovery, the balance sheet carries no debt and the new owner has moved quickly on acquisitions. Against that, this innovator pharma stock already carries an industry level multiple on earnings that fell in FY26. For this innovator pharma stock the evidence available is operational rather than analytical.

Novartis India Share Price Target

No verified brokerage estimate is available, so the honest approach to a Novartis India share price target is to work with levels rather than a published number. The 52-week high of Rs 2,588.80 set on 10 September 2026 is the obvious resistance, and the pre-deal level near Rs 830 shows how far this innovator pharma stock has travelled.

A better anchor for a Novartis India share price target is earnings. If Minipress adds a full year of revenue without margin dilution, sales could move from about Rs 354 crore towards Rs 580 crore, but the financing cost is undisclosed. Until it is, any Novartis India share price target quoted elsewhere is an assumption, not a forecast.

Holders of this innovator pharma stock should watch three dated items: the vote on the name change at the 78th annual general meeting, the funding of the Minipress deal, and the December 2026 quarter, the first full period after the Dr Reddy's arrangement ends.

Other Stocks to Track From the Same Return Screen

Beyond this innovator pharma stock, a screen of NSE small-cap stocks ranked by 1-year return also includes related names such as Senores Pharmaceuticals with a 1-year return of 104.38%, Morepen Labs at 99.55% and Tamilnad Mercantile Bank at 103.95%.

Among the names covered from that screen, MTAR Technologies returned 396.53% over one year. Readers can compare this innovator pharma stock with the Nifty 50 benchmark and track each of these names on Univest before making any decision.

Conclusion

The one-year return of approximately 127% is genuine price appreciation with no split, bonus or special dividend behind it. But the driver of this innovator pharma stock was a change of promoter and a large brand purchase, not a step change in trading performance, and FY26 revenue was lower than FY25.

The setup is binary. If the new owner funds the Minipress purchase sensibly and integrates it without margin damage, the multiple on this innovator pharma stock can be grown into. If funding proves expensive or the distribution transition stumbles, an innovator pharma stock at roughly 52 times trailing earnings with almost no institutional ownership has a long way to fall. Position sizing matters more than conviction here.

Frequently Asked Questions

Which innovator pharma stock has risen 127% in one year?

Ans. Novartis India Ltd (NSE: NOVARTIND) delivered a price return of approximately 127% in the year to 16 September 2026, from about Rs 906 to around Rs 2,053. The gain is clean price appreciation with no split, bonus issue or special dividend in the period.

Why did the Novartis India share price rise so sharply in September 2026?

Ans. The board approved the purchase of the Minipress and Minipres trademarks from Pfizer for approximately Rs 1,250 crore on 7 September 2026. The stock rose about 51% in three sessions and touched a record Rs 2,588.80 on 10 September 2026.

Who owns Novartis India now?

Ans. A ChrysCapital led consortium of WaveRise Investments, ChrysCapital Fund X and Two Infinity Partners holds 70.68%, bought from Novartis AG for about Rs 1,446 crore. The deal closed on 29 July 2026 and Novartis AG no longer holds a stake in the listed entity.

Is this innovator pharma stock being delisted?

Ans. No delisting proposal has been announced. The change of control triggered a mandatory open offer for 26% at Rs 860.64 per share, but only 40 shares were tendered because the market price was far above the offer price, and public shareholding remains close to 29%.

What is the Novartis India share price target for 2026?

Ans. No verified brokerage estimate is available, so there is no published Novartis India share price target to quote. The relevant reference levels are the 52-week high of Rs 2,588.80 and the pre-deal price near Rs 830 from 19 February 2026.

Has this innovator pharma stock paid a special dividend recently?

Ans. No special dividend has been declared. The only payout in the review window was a final dividend of Rs 25 per share with an ex-date of 23 July 2025, giving a dividend yield of approximately 1.1% at the current price.

What are the main risks in this innovator pharma stock?

Ans. Funding the Rs 1,250 crore Minipress purchase against a net worth near Rs 817 crore is the largest risk, followed by a simultaneous change of name, board and distribution partner. Low volumes and a small free float also make this innovator pharma stock prone to sharp moves.

How have the financials of this innovator pharma stock trended?

Ans. Revenue for the year to March 2026 was about Rs 354 crore against Rs 356 crore in FY25, and net profit fell to roughly Rs 93 crore from Rs 101 crore. The June 2026 quarter was better, with revenue near Rs 104 crore, a 34% operating margin and net profit of about Rs 32 crore.